Bristol-Myers Squibb Company (BMY)
$56.77+2.48%
Spriggl Score: Good— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Cash-rich drug giant yielding 4.5%; new medicines must offset two blockbusters losing exclusivity in 2028.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience. The company's products include Opdivo for various…
- Sector:
- Healthcare
- Industry:
- Drug Manufacturers - General
- Market Cap:
- $110.3B
Recent dividends
- 2 Jul 2026$0.63
- 2 Apr 2026$0.63
- 2 Jan 2026$0.63
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Bristol-Myers Squibb Company and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free